<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Ophthalmol</journal-id><journal-id journal-id-type="pmc-domain-id">152</journal-id><journal-id journal-id-type="pmc-domain">brjopthal</journal-id><journal-id journal-id-type="publisher-id">bjophthalmol</journal-id><journal-title-group><journal-title>The British Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0007-1161</issn><issn pub-type="epub">1468-2079</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC1772646</article-id><article-id pub-id-type="pmcid-ver">PMC1772646.1</article-id><article-id pub-id-type="pmcaid">1772646</article-id><article-id pub-id-type="pmcaiid">1772646</article-id><article-id pub-id-type="pmid">15834098</article-id><article-id pub-id-type="doi">10.1136/bjo.2004.050054</article-id><article-id pub-id-type="publisher-id">0890628</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science - Extended Reports</subject></subj-group></article-categories><title-group><article-title>Penetration of moxifloxacin into the human aqueous humour after oral administration</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kampougeris</surname><given-names initials="G">G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Antoniadou</surname><given-names initials="A">A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kavouklis</surname><given-names initials="E">E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chryssouli</surname><given-names initials="Z">Z</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giamarellou</surname><given-names initials="H">H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Ophthalmology, Laiko General Hospital, Athens, Greece</aff><aff id="aff2"><label>2</label>4th Department of Internal Medicine, Athens University School of Medicine, Attikon University General Hospital, Athens, Greece</aff><author-notes><fn><p>Correspondence to: &#133;Mr G Kampougeris &#133;Cardiff Eye Unit, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK; <email>gkampougeris@yahoo.gr</email></p></fn></author-notes><pub-date pub-type="ppub"><month>5</month><year>2005</year></pub-date><volume>89</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">141181</issue-id><fpage>628</fpage><lpage>631</lpage><history><date date-type="accepted"><day>1</day><month>10</month><year>2004</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2008</year></date></event><event event-type="pmc-live"><date><day>30</day><month>04</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2011-07-06 12:30:34.290"><day>06</day><month>07</month><year>2011</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Copyright 2005 British Journal of Ophthalmology</copyright-statement><copyright-year>2005</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bjo08900628.pdf"/><abstract><p><bold>Aims:</bold> To determine the pharmacokinetics of moxifloxacin, a new generation fluoroquinolone, in the anterior chamber of the human uninflamed eye.</p><p><bold>Methods:</bold> 35 patients undergoing cataract surgery received two doses of 400 mg of oral moxifloxacin with a 12 hour interval and were divided into six groups. Moxifloxacin levels in aqueous humour and serum were determined by a microbiological agar well diffusion technique at 2, 4, 6, 8, 10, and 12 hours after the second dose in each group respectively.</p><p><bold>Results:</bold> Mean moxifloxacin levels in the anterior chamber were 1.20 (SD 0.35) &#956;g/ml at the 2 hours group, 1.22 (0.48) &#956;g/ml at the 4 hours group, 1.20 (0.45) &#956;g/ml at the 6 hours group, 1.58 (0.38) &#956;g/ml at the 8 hours group, 1.37 (0.44) &#956;g/ml at the 10 hours group, and 1.23 (0.55) &#956;g/ml at the 12 hours group. The mean ratio of aqueous to serum moxifloxacin level was 38%.</p><p><bold>Conclusion:</bold> Moxifloxacin penetrates well into the anterior chamber of the human uninflamed eye after oral administration, reaching early significant levels, which are maintained for at least 12 hours and are much higher than the MIC<sub>90</sub> values of Gram positive and Gram negative pathogens commonly implicated in intraocular infections with the exceptions of fluoroquinolone resistant staphylococci, MRSA, and <italic>Pseudomonas aeruginosa</italic>.</p></abstract><kwd-group><kwd>moxifloxacin</kwd><kwd>human aqueous humour</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn><p>The authors have no proprietary interest in any of the antimicrobials mentioned in this manuscript.</p></fn></fn-group></notes></front></article></pmc-articleset>